Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing-Remitting Multiple Sclerosis Pipeline Report to explore emerging therapies, key Relapsing-Remitting Multiple Sclerosis Companies, and future Relapsing-Remitting Multiple Sclerosis treatment landscapes @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report
Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report
In June 2025, Novartis Pharmaceuticals announced a study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
In June 2025, Celgene conducted a study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
DelveInsight's Relapsing-Remitting Multiple Sclerosis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment.
The leading Relapsing-Remitting Multiple Sclerosis Companies such as Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Promising Relapsing-Remitting Multiple Sclerosis Therapies such as TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Discover how the Relapsing-Remitting Multiple Sclerosis treatment paradigm is evolving. Access DelveInsight's in-depth Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies
Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile
IMU-838: Immunic AG
Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Currently, the drug is in Phase III stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
IMCY-0141: Imcyse SA
IMCY-0141 Imotope™ is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
ANK-700: Anokion SA
ANK-700 is an investigational therapy developed by Anokion for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). It employs a novel approach known as an ""inverse vaccine,"" aiming to re-educate the immune system to recognize specific myelin proteins as ""self,"" thereby preventing autoimmune attacks on the central nervous system. This strategy seeks to reduce neuroinflammation while preserving overall immune function. Anokion's approach utilizes its proprietary immune tolerance platform, which targets natural pathways in the liver to restore immune tolerance. This liver-targeted antigen strategy effectively expands antigen-specific regulatory T-cells in vivo, offering therapeutic potential across various inflammatory conditions, including multiple sclerosis. ANK-700's innovative mechanism and encouraging early clinical data position it as a promising candidate for future disease-modifying therapies in RRMS. Currently, the drug is in Phase I stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis Treatment.
Relapsing-Remitting Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Relapsing-Remitting Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market.
Get a detailed analysis of the latest innovations in the Relapsing-Remitting Multiple Sclerosis pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs
Relapsing-Remitting Multiple Sclerosis Companies
Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Relapsing-Remitting Multiple Sclerosis Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing-Remitting Multiple Sclerosis Therapies and key Relapsing-Remitting Multiple Sclerosis Developments @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives
Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report
Coverage- Global
Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Relapsing-Remitting Multiple Sclerosis drug development? Find out in DelveInsight's exclusive Relapsing-Remitting Multiple Sclerosis Pipeline Report—access it now! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Relapsing-Remitting Multiple Sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Relapsing-Remitting Multiple Sclerosis– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
IMU-838: Immunic AG
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Telitacicept: RemeGen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ANK700: Anokion
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Relapsing-Remitting Multiple Sclerosis Key Companies
Relapsing-Remitting Multiple Sclerosis Key Products
Relapsing-Remitting Multiple Sclerosis- Unmet Needs
Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers
Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion
Relapsing-Remitting Multiple Sclerosis Analyst Views
Relapsing-Remitting Multiple Sclerosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Prediction: Amazon Stock Will Beat the Market. Here's Why.
Investors who have followed Amazon (NASDAQ: AMZN) for a long time are aware of its path to megacap status. What started as an online bookselling business that pioneered e-commerce has evolved into a tech conglomerate with a $2.2 trillion market cap. While that is a testament to the company's rock-solid business model, it also presents a challenge. Companies that reach such a size tend to grow more slowly, not because of deficiencies in the business model, but instead due to the law of large numbers. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Nonetheless, Amazon is still on track to continue beating the market. Here's why its days of growth are far from over. Amazon's enduring growth drivers Indeed, Amazon's size does not work to its advantage in some respects. As mentioned, higher-percentage growth is harder for large companies to achieve. Moreover, Amazon's largest, most well-known enterprise, online sales, grew its revenue by 6% annually, and it is unclear whether it turns a profit for the company. Fortunately, that business is also well-positioned to serve as a loss leader for other enterprises under Amazon's e-commerce umbrella. Selling digital advertising on the sales site has become a lucrative endeavor, as the $14 billion in revenue it generated in Q1 rose 19% year over year. Subscription services, which includes Amazon Prime, surged 11% higher over the same period to nearly $12 billion. Still, Amazon's primary growth driver stems from the second industry it pioneered: cloud computing. Amazon Web Services (AWS) generated over $29 billion in Q1 revenue. It accounted for 19% of the company's revenue and grew 17% compared to 12 months prior. Additionally, AWS accounted for nearly $12 billion of the more than $18 billion in operating income the company generated in Q1. That strength affords Amazon the opportunity to stay at the forefront of tech by investing in advancements such as artificial intelligence (AI). Furthermore, it means its retailing does not have to earn a profit, better enabling Amazon to compete against retail giants like Walmart and Costco. What the financials and valuations tell us Thus, in Q1, the company's overall revenue of nearly $156 billion was 9% above year-ago levels, influenced in part by the aforementioned law of large numbers. In comparison, Amazon's operating expenses grew 7% over the same period. Other income also shifted from a loss of $2.7 billion to a profit of $2.7 billion during that time, accounting for most of its earnings gain. As such, the company's Q1 net income of over $17 billion increased by 64% during that period. Admittedly, Amazon's free cash flow picture is not so rosy. In Q1, free cash flow was -$8 billion, down from $4 billion in the year-ago quarter. That was primarily because spending on capital expenditures rose from under $15 billion to more than $25 billion amid heavy investment in AI. Investors seem to have largely shrugged off those results. Although the stock is up by only around 10% over the last year, its growth closely approximates that of the S&P 500 's total return. Still, when looking at the five-year chart, Amazon has fallen short of the returns of that index. Nonetheless, that growth rate does not take into account the company's falling earnings multiple. Amazon stock trades at a 34 P/E ratio, down from over 100 in July 2023. That also is lower than Walmart, Costco, and its biggest rival in the cloud space, Microsoft. This implies that Amazon could be a value stock as much as it is a growth stock, and the multiple compression that has reduced Amazon's returns may not last much longer. AMZN PE Ratio data by YCharts Buy Amazon stock Ultimately, Amazon should turn into a market-beater. Indeed, the stock price history over the last five years implies continued underperformance. Nonetheless, Amazon's low P/E ratio looks like a bargain, given the valuations of its most mature retail competitors and its largest cloud peer. Additionally, some of its retail-related businesses are growing revenue rapidly. Moreover, AWS remains tremendously profitable, and the company is investing heavily to stay ahead in the AI race. Such moves often bring rising costs in the short run, but increase the odds of higher returns in future years. In the end, Amazon's large size will likely continue to weigh on the company's percentage growth rates. However, that effect is not likely to be so negative that Amazon can't beat the market in the coming years. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor 's total average return is809% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Costco Wholesale, Microsoft, and Walmart. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
26 minutes ago
- Globe and Mail
Gold Reserve Announces Submission of Further Revised Topping Bid by Dalinar Energy for CITGO Parent Company
Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) (' Gold Reserve ' or the 'Company') announces that today its Delaware subsidiary, Dalinar Energy Corporation (' Dalinar Energy '), submitted a further revised topping bid to be selected as the Final Recommended Bid for the purchase of the shares of PDV Holding, Inc. (' PDVH '), the indirect parent company of CITGO Petroleum Corp., pursuant to the sales process being conducted by the U.S. District Court for the District of Delaware (the ' Court '). Dalinar Energy submitted an initial topping bid on June 3, 2025 as announced here and a revised topping bid on June 18, 2025 as announced here. Terms of the further revised bid will remain confidential until, at the earliest, the Special Master appointed to operate the sale process reviews all bids and makes his final recommendation to the Court by July 2, 2025. The Court is scheduled to hold a sale hearing starting on August 18, 2025, and in connection therewith rule on any objections to the Special Master's final recommendation. Consummation of the further revised bid, if selected and approved by the court, is subject to closing conditions and regulatory approvals, including but not limited to approval by the U.S. Department of Treasury' s Office of Foreign Assets Control (' OFAC '). A complete description of the Delaware sale proceedings can be found on the Public Access to Court Electronic Records system in Crystallex International Corporation v. Bolivarian Republic of Venezuela, 1:17-mc-00151-LPS (D. Del.) and its related proceedings. Cautionary Statement Regarding Forward-Looking statements This release contains 'forward-looking statements' within the meaning of applicable U.S. federal securities laws and 'forward-looking information' within the meaning of applicable Canadian provincial and territorial securities laws and state Gold Reserve's and its management's intentions, hopes, beliefs, expectations or predictions for the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. They are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements contained in this press release include, but are not limited to, statements relating to the Bid. We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause the actual events, outcomes or results of Gold Reserve to be materially different from our estimated outcomes, results, performance, or achievements expressed or implied by those forward-looking statements, including but not limited to: the discretion of the Special Master to consider the Bid, to enter into any discussions or negotiation with respect thereto and that the Special Master may reject the Bid at any time; the Special Master may choose not to recommend a Final Bid to the Court; the failure of the Company to negotiate the Bid, including as a result of failing to obtain sufficient equity and/or debt financing; that Bid submitted by the Company will not be selected as the 'Final Recommend Bid' under the Bidding Procedures, and if selected may not close due to the Sale Process not being completed, including as a result of not obtaining necessary regulatory approvals to close on the purchase of the PDVH shares, including but not limited to any necessary approvals from OFAC, the U.S. Committee on Foreign Investment in the United States, the U.S. Federal Trade Commission or the TSX Venture Exchange; failure of the Company or any other party to obtain any required shareholders approvals for, or satisfy other conditions to effect, any transaction resulting from the Bid; that the Company forfeit any cash amount deposit made due to failing to complete the Bid or otherwise; that the making of the Bid or any transaction resulting therefrom may involve unexpected costs, liabilities or delays; that, prior to or as a result of the completion of any transaction contemplated by the Bid, the business of the Company may experience significant disruptions due to transaction related uncertainty, industry conditions, tariff wars or other factors; the ability to enforce the writ of attachment granted to the Company; the timing set for various reports and/or other matters with respect to the Sale Process may not be met; the ability of the Company to otherwise participate in the Sale Process (and related costs associated therewith); the amount, if any, of proceeds associated with the Sale Process; the competing claims of other creditors of Venezuela, PDVSA and the Company, including any interest on such creditors' judgements and any priority afforded thereto; uncertainties with respect to possible settlements between Venezuela and other creditors and the impact of any such settlements on the amount of funds that may be available under the Sale Process; and the proceeds from the Sale Process may not be sufficient to satisfy the amounts outstanding under the Company's September 2014 arbitral award and/or corresponding November 15, 2015 U.S. judgement in full; and the ramifications of bankruptcy with respect to the Sale Process and/or the Company's claims, including as a result of the priority of other claims. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. For a more detailed discussion of the risk factors affecting the Company's business, see the Company's Management's Discussion & Analysis for the year ended December 31, 2024 and other reports that have been filed on SEDAR+ and are available under the Company's profile at Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Gold Reserve or persons acting on its behalf are expressly qualified in their entirety by this notice. Gold Reserve disclaims any intent or obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of assumptions or factors, whether as a result of new information, future events or otherwise, subject to its disclosure obligations under applicable rules promulgated by the applicable Canadian provincial and territorial securities laws.
CBC
37 minutes ago
- CBC
America's debt: How much is too much?
U.S. debt is sitting at more than $36 trillion US — double what it was 10 years ago — but is that a real problem? Andrew Chang breaks down the numbers to put the severity of the situation in context and explain how a bad situation could get worse.
